Objetivo: Descrever reabilitação estética anterossuperior através de facetas diretas em resina composta. Relato de Caso: Paciente procurou a clínica odontológica, pois estava insatisfeita com seu sorriso. Ao exame clínico foi constatada perda de dimensão vertical, hábitos parafuncionais de bruxismo de vigília e restaurações infiltradas, dentre outros achados. Inicialmente, foi realizada uma profilaxia com pasta à base de pedra-pomes e água, em escova de Robinson, de todas as superfícies dentais; em seguida, após a confecção de uma placa miorrelaxante de acetato, visando controlar o bruxismo, foram realizadas restaurações adesivas nos dentes posteriores com o intuito de aumentar a dimensão vertical de oclusão. Sendo assim, os elementos fraturados que apresentavam férula compatível, optou-se por realizar a reconstrução com pino de fibra de vidro em virtude de eliminar a etapa laboratorial. Posterior a isso foi realizada uma sessão de clareamento de consultório e pôr fim a reabilitação através de facetas diretas em resina composta. Considerações finais: No tratamento reabilitador estético se fazem de extrema importância a destreza e competência do cirurgião-dentista quanto às técnicas e conhecimentos empregados no caso, visando à satisfação e segurança do paciente e êxito do tratamento realizado.

Aldehyde dehydrogenase 1 (ALDH-1) is a marker of stem cells in a variety of diseases, but its role in individuals with chronic inflammatory periapical lesions remains unknown. The aim of this study was to investigate the presence of cells with a stem cell profile based on the immunoexpression of ALDH-1 in periapical granulomas (PGs) and radicular cysts (RCs). A total of 51 cases of periapical lesions (25 PGs and 26 RCs) were subjected to immunohistochemical study. The anti-ALDH-1 antibody was applied using the immunoperoxidase technique. An immunoexpression score (intensity vs. percentage of cells) was used, with the cases being classified as low expression (score: 0 to 4) and high expression (score: 6 to 9). The Chi-square test was used with a 5% level of significance. Immunoexpression of ALDH-1 was detected in all cases of PGs and RCs. In PG cases, the expression was diffuse in connective tissue cells, with most cases exhibiting high expression (n = 18; 69.2%), while in RC cases the expression revealed focal distribution in cells of the capsule and epithelial cells of the cystic lining, with most cases classified as low expression (n = 18; 72%). Significant differences in the expression scores of ALDH-1 were observed in PGs (p = 0.003). The variable expression of ALDH-1 suggests the presence of cells with stem cell profiles in PGs and RCs. These findings suggest that periapical tissues infiltrated by chronic inflammation can recruit important cells for the repair or evolution of periapical lesions.

No Brasil, o câncer é a principal causa de morte por doença em crianças e adolescentes. O Instituto Nacional do Câncer (INCA) estima a ocorrência de 8.460 novos casos de câncer em crianças e adolescentes no ano de 2020.O objetivo desse estudo foi identificar as manifestações bucais mais frequentes nos pacientes pediátricos em tratamento antineoplásico. Essa pesquisa incluiu 137 crianças e adolescentes de 0 a 19 anos de idade. Os dados incluíram um questionário semiestruturado para verificar as manifestações bucais mais frequentes decorrentes da terapia antineoplásica. Os testes estatísticos utilizados foram o teste Qui-quadrado de Pearson e para avaliar a força da associação foi obtido o Odds Ratio (OR) ou Razão das Chances (RC) com respectivo intervalo de confiança. Os resultados encontrados demonstram que a idade média dos pacientes pesquisados foi de 6,8 anos; o sexo masculino (57,7%) foi predominante na amostra; a neoplasia maligna mais incidente foi à leucemia (67,9%); 70,1% dos pacientes apresentaram pelo menos uma manifestação oral, sendo a mucositede maior prevalência (56,2%), seguida da xerostomia (46,7%), gengivite (41,6%), disfagia (35,8%), disgeusia (35,8%), candidíase (34,3%) e herpes (21,2%). Encontraram-se 54,7% dos pacientes com saúde bucal favorável e 40,9% deles com saúde bucal desfavorável. Concluímos que o paciente infantil deve ser avaliado por um odontopediatra previamente ao início da quimioterapia para minimizar as complicações bucais durante o tratamento antineoplásico.

Background: Dysregulation of cyclin D-CDK4/6-Rb pathway is associated with endocrine resistance in hormone receptor–positive (HR+) breast cancer. Recently, a CDK4/6 inhibitor has shown unprecedented efficacy in metastatic disease, leading to its regulatory approval. Several others are currently in clinical development for the management of HR+ breast cancer in the early and advanced settings. However, it is vital to gain insights into the molecular and biological effects of this class of agents and could identify patients who can benefit the most, delaying or avoiding the use of chemotherapy.The neoadjuvant setting provides an ideal scenario to carry out these investigations. Hence, we propose to conduct an exploratory study to evaluate the biological effects and the efficacy of ribociclib in patients with primary luminal B tumors. We hypothesize that the combination of ribociclib plus letrozole may offer clinical benefit in the preoperative setting. Methods: This is a parallel, multicenter, two-arm, randomized exploratory study in postmenopausal women with primary operable HR+/HER2-negative Luminal B breast cancer designed to evaluate the clinical benefit of ribociclib plus letrozole. Eligibility includes stage I-III operable breast cancer, Luminal B by PAM50, ECOG 0-1. They will be randomized 1:1 to receive either six 28-days cycles of ribociclib (600mg; 3-weeks-on/1-week-off) plus daily letrozole (2.5mg) or chemotherapy: four cycles of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks. Baseline, Day 15 on-treatment, and surgical specimens will be collected for molecular characterization and evaluation of response (decrease in Ki67, change to ROR low disease) The primary endpoint is the rate of Residual Cancer Burden (RCB) per MD Anderson Cancer Center procedures. A rate of RCB 0 and 1 score at surgery, with a rank between 20% to 25% with 47 evaluable patients by group of treatment will offer a precision between 11.5% and 12.4%, respectively (95%CI). Ninety-four patients will be enrolled in 21 sites across Spain. The trial was activated in July 2017. As of June 2018, 78 patients have been recruited. Citation Format: Gavila J, Saura C, Oliveira M, Ciruelos E, Gonzalez X, de la Peña L, Bermejo de las Heras B, Muñoz M, Fernandez P, Villagrasa P, Ortega V, Lopez R, Celiz P, Pascual T, Prat A. CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-02-05.

No abstract